TRIM21

Across TCGA pan-cancer cohorts, TRIM21 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRIM21 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TRIM21 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRIM21 expression acts as an unfavorable survival marker.

STAD, LUAD, and BRCA are the cancer types where TRIM21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	0.075	0.629	<.001	25	view →
LUAD	OS	Median	II,III,IV	0.053	0.751	<.001	22	view →
BRCA	OS	Median	III,IV	0.211	0.833	<.001	20	view →
LUSC	OS	Median	III,IV	0.011	0.684	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	II,III,IV	0.556	0.850	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRIM21–STAD (OS)

Open the STAD breakdown →